Sublingual Tofacitinib for Alopecia Areata: A Roll-Over Pilot Clinical Trial and Analysis of Pharmacokinetics

    Vivien Wai Yun Lai, Laita Bokhari, Rodney Sinclair
    From the encyclopedia
    Tofacitinib →

    a JAK inhibitor for alopecia areata and other autoimmune conditions

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results